

## MLA secures exclusive licence for distribution of market-leading nanofiber technology for animals

- **Exclusive distribution licence secured from Nanofiber Veterinary in three major markets**
- **MLA and Nanofiber technology complementary – agreement expands possibilities for use in MLA’s own stem cell applications**
- **Valuable step in broadening MLA’s animal healthcare portfolio**

**Sydney, 3 July 2014:** Human and animal healthcare company Medical Australia Limited (“MLA”, the “Company”) is pleased to announce that through its MediVet Animal Health business, it has secured an exclusive licensing agreement from Nanofiber Veterinary for distribution of NanoWhiskersV™ and NanoCareV™ product lines in Australia, Japan, and the United States.

The innovative product lines provide a valuable adjunct to MediVet’s already established adipose-derived stem cell technology to further enhance the treatment of a variety of degenerative conditions and diseases in animals including but not limited to osteoarthritis. The Nanofiber technology provides a supportive framework and an optimal healing environment for stem cells to proliferate, differentiate and regenerate damaged tissues.

NanoWhiskersV™ use injectable FDA-approved polymer fibres to increase cellular localisation in the area of ailment to regenerate joints. NanoWhiskersV™, when administered with MediVet’s adipose-derived stem cell therapy, results in stem cells binding to the scaffolding matrix and guides cellular growth causing cells to replicate and differentiate to form fully functional tissues. This further enhances the overall effectiveness of joint regeneration.

NanoCareV™ provides expedited healing of all types of wounds in animals. The NanoCareV™ is a durable, bio-stable mesh with an allogeneic graft base (temporary skin substitute) that is placed directly over a wound followed by a series of seeded and non-seeded autologous stem cells or Platelet Rich Plasma (PRP). Stem cells and PRP are applied to wounds for their regenerative properties that enable differentiation into skin tissue to heal wounds, some of which may have been deemed as untreatable in the past.

The technology from Nanofiber Solutions vastly increases the scope of application of MediVet’s Stem Cell Technology and PRP for the treatment of wounds, joint injury and joint degeneration in both small animal and equine patients on a global scale providing a platform for growth.

MLA Chief Operating Officer Darryl Ellis commented: “This is a pleasing development for MLA, as these products are not only complementary to our own stem cell therapies, they will further enable and broaden their use and application.”

Nanofiber Veterinary offers a wide variety of novel, synthetic nanofiber scaffolds developed by Nanofiber Solutions, which recently made history in designing the first synthetic tracheas implanted into human patients – four people across the world have now received life-saving tracheal implants made by Nanofiber Solutions.

Timm Peddie, President of Nanofiber Veterinary, added: “We are excited for our partnership with Medical Australia Limited, due to the complimentary nature of our products and their expertise in the field with existing brand traction in these key markets.”

MLA will now collaborate with Nanofiber Veterinary to continue ongoing research projects to achieve increased efficacy, continued learning and promote hands on access to veterinary regenerative medicine.



Mr Ellis concluded: “Through the MediVet and TUTA Vet brands, MLA now has a strong and growing suite of products for the animal health industry that we continue to develop and enhance. We are now uniquely positioned to take advantage of our existing technologies and maintain our leadership in the field of regenerative medicine in veterinary applications.”

“MLA also looks forward to further updating shareholders on the Company’s operations in FY 2014 over the coming months.”

- ENDS –

**For more information contact:**

Darryl Ellis

Chief Operating Officer

Medical Australia

Ph: +61 2 9466 5300

Media please contact: Ben Jarvis, Six Degrees Investor Relations: +61 413 150 448

**ABOUT MEDICAL AUSTRALIA LIMITED**

*Medical Australia Limited (ASX: MLA) is a human and animal healthcare company engaged in the manufacture, distribution and sale of a broad range of medical and veterinary devices used by healthcare facilities, critical care services and veterinarians in global markets. The Company is a leader in Intravenous (IV) Medication Delivery Systems, Surgical Irrigation, Suction and Oxygen Therapy, Safety Sharps Collection and Reuse Prevention and specialised Diagnostic and Laboratory Equipment. Our products are used in three broad areas of healthcare, Human Health; Biological Collection, Processing and Laboratory; and Animal Health. Through the acquisition of MediVet Pty Ltd Medical Australia now has proprietary ownership of technology for regenerative medicine including stem cell therapy for domestic animals and the equine industry. Medical Australia’s animal health business is now represented in major countries and regions such as Canada, USA, Great Britain, Continental Europe, Australia and the Asia Pacific Region, including a 60.5% interest in MediVet America LLC.*

**ABOUT NANOFIBER VETERINARY**

*Nanofiber Veterinary™ offers advanced veterinary products and works with leaders in life science research. The company partners with leading veterinary researchers, surgeons, and veterinary clinics around the world. Nanofiber Veterinary™ offers the only translational 3D cell culture products, with a growing host of tissue scaffolds for the veterinary market. The company is based in Reno, Nevada, United States.*

**For more information**

[press@nanofiberveterinary.com](mailto:press@nanofiberveterinary.com)

[www.nanofiberveterinary.com](http://www.nanofiberveterinary.com)

ABN: 30 096 048 912  
Unit 4B, 128-130 Frances St, Lidcombe, NSW, 2141, Australia  
PO BOX 445, Lidcombe, NSW, 2141  
T +612 9466 5300 F +612 9922 7165  
[www.medaust.com](http://www.medaust.com)